Human Relaxin-2Interpret the evidence
Why the Large Serelaxin Trial Did Not Confirm a Benefit in Acute Heart Failure
2 numbered sourcesSource years 2019, 2026
Peptides are short amino-acid chains connected by peptide bonds. Some circulate as hormones and influence blood flow or the way organs respond to changes in demand. Human relaxin-2 is a peptide hormone involved in cardiovascular and renal adaptations during pregnancy. Serelaxin is a recombinant form of human relaxin-2. Its effects on blood vessels provided a reason to test it in acute heart failure, when a person is hospitalized with worsening symptoms such as shortness of breath and fluid congestion. The older RELAX-AHF-2 trial is the direct human test of that question. [1]
Marco Metra and colleagues reported results for 6,545 participants in a randomized, double-blind comparison. Both groups received standard care. One also received serelaxin and the other a placebo. The team selected two primary outcomes in advance: cardiovascular death by 180 days and worsening heart failure by day five. The first tested a longer-term outcome and the second a near-term deterioration during an acute episode. Setting those outcomes in advance gave readers a clear basis for deciding whether the main hypothesis was supported. [1]
Cardiovascular death occurred in 8.7 percent of the serelaxin group and 8.9 percent of the placebo group. Worsening heart failure by day five occurred in 6.9 and 7.7 percent, respectively. The differences did not reach statistical significance, and the estimated ranges of plausible effects did not exclude no difference. The researchers also reported similar overall adverse-event incidence in the two groups. The trial did not demonstrate benefit on either primary outcome. [1]
In 2026, a separate study observed effects of serelaxin on fibrotic changes in mouse models. That is a useful mechanistic result with a different endpoint and setting. It does not overturn the randomized comparison in hospitalized people. It also cannot show which patients might respond differently without new direct evidence. The two papers can coexist: a molecule can affect tissue biology in an experimental model while failing to improve the specified clinical outcomes under the conditions of a large trial. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
